Sellas Life Sciences Group Inc
(SLS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 13,986 | 2,630 | 17,225 | 21,455 | 35,402 |
| Other current assets | 0 | 0 | 0 | 0 | 1,128 |
| TOTAL | $16,327 | $3,172 | $17,756 | $23,044 | $36,925 |
| Non-Current Assets | |||||
| Intangibles | 1,914 | 1,914 | 1,914 | 1,914 | 1,914 |
| Other Non-Current Assets | 1,191 | 1,133 | 1,273 | 1,317 | 7,210 |
| TOTAL | $3,105 | $3,047 | $3,187 | $3,231 | $9,124 |
| Total Assets | $19,432 | $6,219 | $20,943 | $26,275 | $46,049 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,500 | 5,639 | 8,857 | 2,144 | 4,657 |
| Accrued Expenses | 5,466 | 7,650 | 6,286 | 2,640 | 1,913 |
| TOTAL | $9,510 | $13,735 | $15,515 | $4,982 | $12,336 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | N/A | N/A | 5,600 |
| Other Non-Current Liabilities | 457 | 460 | 577 | 946 | 5,513 |
| TOTAL | $457 | $460 | $577 | $946 | $5,752 |
| Total Liabilities | $9,967 | $14,195 | $16,092 | $5,928 | $18,088 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 90,847 | 56,268 | 28,303 | 15,906 | 15,085 |
| Common Shares | 7 | 3 | 2 | 2 | 1 |
| Retained earnings | -248,125 | -217,244 | -179,904 | -138,603 | -117,904 |
| TOTAL | $9,465 | $-7,976 | $4,851 | $20,347 | $27,961 |
| Total Liabilities And Equity | $19,432 | $6,219 | $20,943 | $26,275 | $46,049 |